Search company, investor...


Seed | Alive

Total Raised


Last Raised


About Emerge

Emerge helps make companies and processes super-efficient. Emerge does this through a SaaS solution that delivers customized machine-learning models across the customer value chain. Emerge's models are very accurate and quick to build. Emerge works in partnership with trusted consulting companies, software giants and directly with corporates to develop constantly-learning operational solutions to valuable and consequential problems.

Headquarters Location

International House 1 St Katharine's Way, No.1 London Bridge

London, England, E1W,

United Kingdom



Latest Emerge News

AI Meets Oncology! Mainz Biomed Inks Pact With Liquid Biosciences To Develop Next-Gen Colorectal Cancer Screening Test

Nov 7, 2023

Loading... Mainz Biomed N.V. MYNZ inked a pact with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE), to enhance the  detection and diagnosis of colorectal cancer (CRC). Key attributes of EMERGE that make it superior to mainstream AI and machine learning analytical solutions include its computational speed, ability to handle millions of variables, and ability to operate agnostically  without any assumptions or constraints. The partnership expands on Mainz Biomed's initial deployment of EMERGE for examining the ColoFuture study's findings, which revealed promising results, including a 94% sensitivity for detecting colorectal cancer with a specificity of 97% and an 80% sensitivity for identifying advanced adenomas. According to the agreement, the application of EMERGE within Mainz Biomed's development pipeline will now also encompass the examination of its eAArly DETECT study (the U.S. segment of the ColoFuture clinical trial), as well as the upcoming U.S. pivotal FDA PMA trial (ReconAAsense), which could, upon positive outcomes, allow Mainz Biomed to enhance the existing test's performance and bring to market a new benchmark for self-administered CRC screening tools. The eAArly DETECT clinical trial, a multi-center feasibility study, is proceeding with the enrollment of 265 participants across 22 sites and is anticipated to share its findings in Q4 2023. The end goal is to create a singular, stable machine learning/AI-based algorithm using the evolutionary EMERGE platform, to be incorporated into the reporting mechanism of the forthcoming product generation. Since launching the EMERGE bio-analytics platform, Liquid Biosciences is widely considered to be the premier analytical partner to the life sciences industry. Its technology has been deployed in over 240 projects for Big Pharma and emerging therapeutic and diagnostic companies. "As artificial intelligence continues to disrupt every aspect of the healthcare  sector , we are excited to establish a robust partnership with a genuine leader in the field as we head into the final development stage of our next-generation CRC screening test," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. Price Action: MYNZ shares are trading higher by 9.09% to $3.00 on the last check Tuesday. Loading...

Emerge Frequently Asked Questions (FAQ)

  • Where is Emerge's headquarters?

    Emerge's headquarters is located at International House, London.

  • What is Emerge's latest funding round?

    Emerge's latest funding round is Seed.

  • How much did Emerge raise?

    Emerge raised a total of $20K.

  • Who are the investors of Emerge?

    Investors of Emerge include Startupbootcamp FinTech Dubai.

  • Who are Emerge's competitors?

    Competitors of Emerge include r4 Technologies and 4 more.


Compare Emerge to Competitors

Kuiper Data Technologies

Kuiper Data Technologies is a company focused on providing augmented decision-making solutions in the data analysis and industrial manufacturing sectors. The company offers a conversational AI decision platform, JarviX, which serves as an end-to-end data analysis platform aimed at reshaping the management mode of industrial manufacturing enterprises. It also provides a product named ODIN 5G Gateway, which facilitates one-stop data collection, transmission, and analysis, supporting predictive maintenance of equipment and efficient optimization of production resource allocation. The company primarily serves the manufacturing industry. It is based in Cambridge, Massachusetts.

Sisense Logo

Sisense operates as a company focused on data analytics in the technology sector. It offers a platform that allows businesses to integrate intelligent analytics into their products, converting data into actionable insights. It primarily serves sectors such as retail, life sciences, and manufacturing. It was founded in 2004 and is based in New York, New York.

Xeler8 Logo

Xeler8 is a startup tracker for investors and a lead generator platform for corporations. With the platform users can discover, track and analyze startups and private companies across 50 industries.

Rockmetric Logo

Rockmetric is a customer data management and analytics platform that helps users create a unified user profile across web, mobile, email, telephony, support, CRM, social and other tools to drive innovation in customer experience.

Chata Logo

Chata offers self-service analytics solutions. It offers a conversational analytics assistant that allows users to access, search and analyze business data with natural human language. The company was founded in 2017 and is based in Calgary, Canada.

Macheye Logo

Macheye provides personalized business analytics systems. The company's augmented analytics platform designs to empower organizations to analyze data more effectively and gain valuable insights to optimize businesses. It was founded in 2018 and is based in Fremont, California.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.